Portal Vein Thrombosis Clinical Trials

8 recruiting

Portal Vein Thrombosis Trials at a Glance

8 actively recruiting trials for portal vein thrombosis are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Yangzhou, Beijing, and Freiburg im Breisgau. Lead sponsors running portal vein thrombosis studies include Northern Jiangsu People's Hospital, Mansoura University, and Asian Institute Of Medical Sciences.

Browse portal vein thrombosis trials by phase

Treatments under study

About Portal Vein Thrombosis Clinical Trials

Looking for clinical trials for Portal Vein Thrombosis? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Portal Vein Thrombosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Portal Vein Thrombosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

Freiburg TIPS Registry

Liver CirrhosisPortal Vein ThrombosisPortal Hypertension+3 more
University Hospital Freiburg2,000 enrolled1 locationNCT05782556
Recruiting
Phase 4

Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis

CirrhosisAscitesPortal Vein Thrombosis+3 more
Asian Institute Of Medical Sciences220 enrolled1 locationNCT07521332
Recruiting
Not Applicable

Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS

CirrhosisPortal Vein ThrombosisHypertension, Portal+1 more
Northern Jiangsu People's Hospital20 enrolled1 locationNCT07461545
Recruiting
Not Applicable

Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD

CirrhosisPortal Vein ThrombosisHypertension, Portal+1 more
Northern Jiangsu People's Hospital20 enrolled1 locationNCT07461532
Recruiting

Indicators Affecting PVT Recanalization

CirrhosisPortal Hypertension Related to CirrhosisPortal Vein Thrombosis+1 more
Shanghai Zhongshan Hospital1,500 enrolled1 locationNCT07473375
Recruiting

A Study of the Correlation Between Portal Vein Thrombosis and Prognosis of Liver Transplantation

Portal Vein Thrombosis
Ru-zhou Cai700 enrolled1 locationNCT06513780
Recruiting
Phase 4

Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC

CirrhosisHCC - Hepatocellular CarcinomaPortal Vein Thrombosis
Mansoura University100 enrolled1 locationNCT07132515
Recruiting
Phase 2

Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion

Hepatocellular CarcinomaPortal Vein Thrombosis
Samsung Medical Center63 enrolled1 locationNCT05625893